Abstract
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma resulting in improved clinical outcomes, however approximately 50% of patients ultimately develop resistance and progress on ICPI. Significant clinical morbidity...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
